Mounjaro's competitors in UK weight management: what the evidence actually shows

The misconception: that all weight-loss injections do the same thing

People often assume that Mounjaro, Wegovy and older medicines like Saxenda are essentially interchangeable, different brands, same result. That is not quite right, and the mechanism matters more than the marketing.

Mounjaro's active ingredient, tirzepatide, binds to both the GIP receptor and the GLP-1 receptor. Wegovy's active ingredient, semaglutide, binds only to GLP-1. Both slow gastric emptying and reduce appetite, but the dual-receptor approach in tirzepatide appears to produce a stronger signal, which is reflected in the trial results. The tirzepatide overview at nume covers the mechanism in more detail if you want to go further into the biology.

Orlistat is a different category entirely. It is a lipase inhibitor taken with meals that blocks roughly a third of dietary fat from being absorbed. It has no effect on appetite hormones, does not slow digestion in the same way, and is considerably less effective by average weight-loss figures. It is also available without a prescription at lower strengths. For most people asking about Mounjaro's competitors, orlistat is the starting point of the conversation rather than the finishing line.

Saxenda (liraglutide), another GLP-1 injection, is UK-licensed for weight management but is dosed daily rather than weekly and is associated with smaller average weight losses in trials. It is not dispensed by nume and is steadily being superseded by once-weekly options.

How the trial evidence stacks up, carefully

Direct comparisons between medicines are rare in clinical research. The most important one here is SURMOUNT-5, an open-label trial published in the New England Journal of Medicine in 2025 that randomised 751 adults with obesity and no diabetes to either tirzepatide or semaglutide 2.4 mg for 72 weeks. Tirzepatide produced greater average weight reduction. That is the closest thing to a controlled head-to-head the field has.

For context on individual medicines: SURMOUNT-1 (tirzepatide, 72 weeks) found average body-weight reductions of around 20–21% at the 15 mg dose. The STEP 1 trial of semaglutide 2.4 mg found around 15% over 68 weeks, as reported on the NHS semaglutide medicines page. The newer 7.2 mg semaglutide dose (approved as a dedicated single-dose pen by the MHRA in April 2026) reported around 20.7% average loss over 72 weeks in its trials, which substantially narrows the gap.

There are caveats worth sitting with. Trial populations differ. Individual responses vary considerably. A medicine that produces 20% average loss across thousands of participants might produce 10% or 28% for a given person. Average figures describe groups, not individuals. A clinician reviewing your full health picture will weigh that alongside your medical history, any other medicines you take, and your own preferences.

NICE, the NHS and what that means for access in practice

NICE has appraised both main competitors. Tirzepatide was recommended in TA1026 (December 2024, updated September 2025) for adults with a BMI of 35 or above plus at least one weight-related condition, with phased NHS rollout underway. Semaglutide (Wegovy) was recommended in TA875 for use within specialist weight management services for a maximum of two years, under similar eligibility thresholds. Both appraisals apply lower BMI thresholds for certain ethnic backgrounds.

NHS access for either medicine involves waiting lists, eligibility criteria and referral pathways that are still being built out across England, and vary in Scotland, Wales and Northern Ireland. The oral Wegovy tablet, approved by the MHRA in June 2026 as the first oral GLP-1 medicine licensed in the UK for weight management, is not yet available on the NHS; a NICE appraisal would need to happen first.

For people exploring private routes, it helps to read about how Mounjaro compares across provider types and to understand that the cost picture is part of the decision. A single transparent price that includes clinical assessment, prescription and aftercare is a different proposition to a headline figure that separates those elements out. You can read more about how Mounjaro's UK pricing has shifted since Eli Lilly's list-price change in September 2025, which affected what private providers charge.

Choosing between them is a clinical conversation, not a search result

The practical reality is that most people cannot simply pick their preferred weight-loss medicine and order it. These are prescription-only medicines, and a prescriber makes the clinical call based on your BMI, your medical history, any contraindications, and what you are already taking. Someone on an oral contraceptive, for example, needs specific guidance around tirzepatide because absorption of the pill may be reduced, adding a barrier method for the first four weeks of treatment and after each dose increase is advised. If you are trying to understand where you can find tirzepatide through legitimate routes, knowing which types of provider and service are involved is a useful place to start. That kind of nuance does not appear in a comparison article.

The thing patients often tell our prescribers they wish they had known earlier is that the choice of medicine matters less than whether the clinical picture supports using one at all. Keep your pen in the fridge door where you will see it as part of your weekly routine, whichever one you end up on, consistency with the injection schedule is what makes the titration work.

If you are weighing up options and want a proper assessment from a clinician rather than another ranking, start a free consultation with our prescribers. A GPhC-registered independent prescriber reads every submission the same day. There are no subscriptions, no automatic renewals, and no hidden fees, just a straightforward clinical decision made with you, not for you. You can also read about the treatment options we offer, find out more about the companies involved in supplying Mounjaro, understand what getting Mounjaro from a doctor typically involves, or browse our FAQs page.